NovaBay Pharmaceuticals (NYSE:NBY) announced today that it agreed with Okra Limited to distribute its Zocular dry eye products.
The agreement allows NovaBay to distribute Zocular dry eye products alongside Avenova in its physician-dispensed sales channel.
Zocular products are formulated with patented Zokrex technology, which contains activated natural okra polysaccharide complexes designed to gently and effectively clear Demodex, scurf and residue from eyelids. They include easy-to-use, in-office and at-home treatment options.
The ZocuKit for ZEST (Zocular Eyelid System Technology) provides a 10-minute, in-office procedure that is clinically proven to offer dramatic, immediate lasting results for dry eye. ZEST requires no capital equipment or topical anaesthetic, according to a news release.
Additionally, Okra offers ZocuWipe, a once-daily, disposable towel for neutralizing and removing dirt, oil and debris, ZocuFoam, a gentle eyelid cleaning and moisturizing foam and finally ZocuShield, an easy-to-apply gel-filled syringe.
“We’ve been searching for additional dry eye products to add to our established sales channels for some time. The Zocular product line is ideal for eyecare specialists seeking effective tools to treat their patients’ dry eye and is a perfect complement to Avenova,” NovaBay CEO Justin Hall said in the release. “Zocular products are formulated with a novel, powerful technology to address inflammation at the eyelid margin. Avenova is the only lid and lash antimicrobial spray to be clinically proven to reduce the bacterial load on skin surfaces surrounding the eyes, thus addressing the underlying cause of bacterial dry eye. Both Avenova and Zocular at-home products are completely safe for regular use.”
